A Study to Investigate Safety, Tolerability, and Pharmacokinetics of Oral AZD0233 Compared With Placebo in Healthy Adult Participants.
← catalyst calendarSponsored by AstraZeneca (industry) · AZN — their whole pipeline →. With Parexel.
Phase
Phase 1
Status
Terminated
Study type
Interventional
Design
Randomized · Triple · Treatment
Enrollment
84actual
Sites
1
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Why the sponsor stopped it
The study has been terminated due to adverse finding in a non-clinical, chronic toxicology study.
As filed on the registry record, in the sponsor's own words.
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-04-01 | actual | When the study began enrolling |
| Primary completion | 2025-12-30 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-12-30 | actual | The whole study's end, after follow-up |
| First posted | 2024-04-24 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-01-26 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Dilated Cardiomyopathy
Interventions
- Drug: AZD0233
- Drug: AZD0233 Placebo — also filed as Placebo
Primary outcome
what the primary-completion date above is the date OFNumber of participants with adverse events (AEs) and serious adverse events (SAEs)
measured From screening (Day -28) to follow-up visit (Day 17)
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed